Amgen Stock Rises 1.53% as $510M Volume Ranks 232nd on Q2 Revenue and EPS Outperformance

On August 13, 2025, Amgen (NASDAQ:AMGN) rose 1.53% with a trading volume of $510 million, ranking 232nd in daily equity activity. The biotech giant reported Q2 revenue of $9.18 billion, surpassing estimates by 2.7% year-on-year, driven by volume growth in general medicine, rare diseases, and oncology. Non-GAAP earnings per share reached $6.02, exceeding analyst forecasts by 14.1%, while the company raised its full-year revenue guidance to $35.5 billion at the midpoint, reflecting confidence in key product demand and late-stage pipeline advancements.

Management highlighted 15 products achieving double-digit sales growth, including Repatha, EVENITY, and UPLIZNA, though acknowledged pricing pressures from biosimilars and legacy products like Prolia. CEO Robert Bradway emphasized strategic expansion in therapeutic areas and AI-driven R&D efficiency, while CFO Peter Griffith reiterated commitment to financial discipline amid regulatory uncertainties. Analyst questions during the earnings call focused on MariTide’s obesity trial progress, Medicaid reforms, and rare disease M&A opportunities, underscoring near-term catalysts.

A backtested trading strategy involving the top 500 stocks by daily volume from 2022 to 2025 yielded a compound annual growth rate of 6.98%, with a maximum drawdown of 15.46% recorded in mid-2023. The strategy demonstrated steady returns despite volatility, highlighting the importance of risk mitigation in high-turnover equities.